Unlike larger companies, ALPS lacks a set of credible analyst price targets. Sell-side coverage is essentially nonexistent, and any third-party numbers that surface tend to be inconsistent or unreliable. I therefore treat this as a technical recovery discussion rather than a fundamentals-driven forecast.
The $1.50 level comes from market commentary focused on the stock's prior consolidation zones after its long decline from a 52-week high near $8.60. It is a publicly discussed technical objective, not a broker-issued target.
Shares recently closed near $1.18, placing the market capitalization around $37–39 million within a 52-week range of roughly $1.01 to $8.60. A move to $1.50 would represent an approximate 27% advance—meaningful for any micro-cap, especially one that has already lost most of its value.
Fundamentals remain limited, with trailing-twelve-month revenue in the low single-digit millions and ongoing net losses. Any advance would likely stem from sentiment shifts, financing news, partnership announcements, or pipeline progress rather than improved current earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The long-term chart remains damaged, with shares near the bottom of the 52-week range. The $1.50 area stands out as a round-number psychological level that previously served as a consolidation zone. Support to watch lies at the $1.01 low, while any move above $1.50 would encounter layers of prior trading activity and resistance as the stock tries to repair its downtrend.
Because the target is technical rather than analyst-derived, there is no formal research timeline. I keep an eye on quarterly results and cash position, updates to the research pipeline, any financing or partnership news, and changes in share count that might indicate dilution. Broader conditions in small-cap biotech also matter, along with price action around the $1.01 support and $1.50 resistance levels.
One tool I often turn to for names like this is AI Daily Buy/Sell Signals from Tickeron. These signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold recommendations based on technical behavior and shifting market conditions. For a low-liquidity micro-cap where traditional coverage is scarce, the system helps surface trend changes and emerging opportunities more efficiently than manual review alone. Traders looking to streamline daily analysis can explore these signals as a complement to their own work.
The $1.50 objective for ALPS is a technical recovery level drawn from public discussion, not a published analyst consensus. Reaching it would require a substantial gain of roughly 27% from recent prices near $1.18. Supporting the case are the stock’s tiny market capitalization, low float, and deeply depressed valuation, which could magnify any positive catalyst. Working against it are persistent losses, minimal revenue, illiquidity, dilution risk, and a severely damaged long-term chart. Whether ALPS can reach $1.50 will depend heavily on business milestones, financing, and sentiment in speculative biotech, and investors should weigh those factors carefully rather than treat the figure as a forecast or a certainty.
In my own workflow I regularly use Tickeron’s AI tools to cross-check ideas and monitor low-coverage names. The platform’s AI Daily Buy/Sell Signals and related engines help me stay on top of technical shifts without spending hours on manual screening. I find them especially useful when traditional analyst data is thin or unavailable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALPS declined for three days, in 62 of 79 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALPS as a result. In 22 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 32%.
The Moving Average Convergence Divergence Histogram (MACD) for ALPS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 14 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 27%.
The 10-day moving average for ALPS crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 33%.
The Aroon Indicator for ALPS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPS advanced for three days, in 35 of 71 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
ALPS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (3.592). P/E Ratio (0.000) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (13.699) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. ALPS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology